Search
60 Degrees Pharmaceuticals Inc
SXTPAdd to Watchlist
1.710USD
-0.040-2.29%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
1.75MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-02The current earnings forecast score of 60 Degrees Pharmaceuticals Inc is 7.00, ranking 111 out of 157 in the Pharmaceuticals industry. The average price target is 4.40, with a high of 6.00 and a low of 2.80.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
3.700
Target Price
+111.43%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
177
Total
6
Median
8
Average
Company name
Ratings
Analysts
60 Degrees Pharmaceuticals Inc
SXTP
2
Biogen Inc
BIIB
38
Amgen Inc
AMGN
38
Eli Lilly and Co
LLY
35
Vertex Pharmaceuticals Inc
VRTX
34
AbbVie Inc
ABBV
33
1
2
3
...
36
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is 60 Degrees Pharmaceuticals Inc's expected revenue for the next quarter?
60 Degrees Pharmaceuticals Inc's expected revenue is 185.00K.
What is 60 Degrees Pharmaceuticals Inc's price target?
Analysts forecast that 60 Degrees Pharmaceuticals Inc's price target is USD 4.40, with the highest forecast at USD 6.00 and the lowest forecast at USD 2.80.
How have 60 Degrees Pharmaceuticals IncSXTP's recent earnings per share performed?
The market expectation was USD -1.28, while 60 Degrees Pharmaceuticals IncSXTP's earnings per share (EPS) for the previous quarter was USD -1.47. EPS for the next quarter is expected at USD -0.68.
What is the analyst rating for 60 Degrees Pharmaceuticals Inc?
Based on the ratings of 60 Degrees Pharmaceuticals Inc's stock from 2 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.